4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition

Travis J. Riedel, John Knight, Michael S. Murray, Dawn S. Milliner, Ross P. Holmes, W. Todd Lowther

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Mutations in the gene encoding for 4-hydroxy-2-oxoglutarate aldolase (HOGA) are associated with an excessive production of oxalate in Primary Hyperoxaluria type 3 (PH3). This enzyme is the final step of the hydroxyproline degradation pathway within the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate. No analyses have been performed to assess the consequences of the mutations identified, particularly for those variants that produce either full-length or nearly full-length proteins. In this study, the expression, stability, and activity of nine PH3 human HOGA variants were examined. Using recombinant protein produced in Escherichia coli as well as transfected Chinese hamster ovary (CHO) cells, it was found that all nine PH3 variants are quite unstable, have a tendency to aggregate, and retain no measurable activity. A buildup of HOG was confirmed in the urine, sera and liver samples from PH3 patients. To determine how HOG is cleaved in the absence of HOGA activity, the ability of N-acetylneuraminate aldolase (NAL) to cleave HOG was evaluated. NAL showed minimal activity towards HOG. Whether the expected buildup of HOG in mitochondria could inhibit glyoxylate reductase (GR), the enzyme mutated in PH2, was also evaluated. GR was inhibited by HOG but not by 2-hydroxyglutarate or 2-oxoglutarate. Thus, one hypothetical component of the molecular basis for the excessive oxalate production in PH3 appears to be the inhibition of GR by HOG, resulting in a phenotype similar to PH2.

Original languageEnglish (US)
Pages (from-to)1544-1552
Number of pages9
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1822
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

4-hydroxy-2-oxoglutarate aldolase
glyoxylate reductase
Primary Hyperoxaluria
Fructose-Bisphosphate Aldolase
Oxalates
Mitochondria
alpha-ketoglutaric acid
Mutation
Hydroxyproline
Enzymes

Keywords

  • Calcium oxalate stone disease
  • Hydroxyproline
  • Oxalate

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. / Riedel, Travis J.; Knight, John; Murray, Michael S.; Milliner, Dawn S.; Holmes, Ross P.; Lowther, W. Todd.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1822, No. 10, 10.2012, p. 1544-1552.

Research output: Contribution to journalArticle

Riedel, Travis J. ; Knight, John ; Murray, Michael S. ; Milliner, Dawn S. ; Holmes, Ross P. ; Lowther, W. Todd. / 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2012 ; Vol. 1822, No. 10. pp. 1544-1552.
@article{bea8455963ba48fa8fb2b52b85a2a5ac,
title = "4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition",
abstract = "Mutations in the gene encoding for 4-hydroxy-2-oxoglutarate aldolase (HOGA) are associated with an excessive production of oxalate in Primary Hyperoxaluria type 3 (PH3). This enzyme is the final step of the hydroxyproline degradation pathway within the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate. No analyses have been performed to assess the consequences of the mutations identified, particularly for those variants that produce either full-length or nearly full-length proteins. In this study, the expression, stability, and activity of nine PH3 human HOGA variants were examined. Using recombinant protein produced in Escherichia coli as well as transfected Chinese hamster ovary (CHO) cells, it was found that all nine PH3 variants are quite unstable, have a tendency to aggregate, and retain no measurable activity. A buildup of HOG was confirmed in the urine, sera and liver samples from PH3 patients. To determine how HOG is cleaved in the absence of HOGA activity, the ability of N-acetylneuraminate aldolase (NAL) to cleave HOG was evaluated. NAL showed minimal activity towards HOG. Whether the expected buildup of HOG in mitochondria could inhibit glyoxylate reductase (GR), the enzyme mutated in PH2, was also evaluated. GR was inhibited by HOG but not by 2-hydroxyglutarate or 2-oxoglutarate. Thus, one hypothetical component of the molecular basis for the excessive oxalate production in PH3 appears to be the inhibition of GR by HOG, resulting in a phenotype similar to PH2.",
keywords = "Calcium oxalate stone disease, Hydroxyproline, Oxalate",
author = "Riedel, {Travis J.} and John Knight and Murray, {Michael S.} and Milliner, {Dawn S.} and Holmes, {Ross P.} and Lowther, {W. Todd}",
year = "2012",
month = "10",
doi = "10.1016/j.bbadis.2012.06.014",
language = "English (US)",
volume = "1822",
pages = "1544--1552",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition

AU - Riedel, Travis J.

AU - Knight, John

AU - Murray, Michael S.

AU - Milliner, Dawn S.

AU - Holmes, Ross P.

AU - Lowther, W. Todd

PY - 2012/10

Y1 - 2012/10

N2 - Mutations in the gene encoding for 4-hydroxy-2-oxoglutarate aldolase (HOGA) are associated with an excessive production of oxalate in Primary Hyperoxaluria type 3 (PH3). This enzyme is the final step of the hydroxyproline degradation pathway within the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate. No analyses have been performed to assess the consequences of the mutations identified, particularly for those variants that produce either full-length or nearly full-length proteins. In this study, the expression, stability, and activity of nine PH3 human HOGA variants were examined. Using recombinant protein produced in Escherichia coli as well as transfected Chinese hamster ovary (CHO) cells, it was found that all nine PH3 variants are quite unstable, have a tendency to aggregate, and retain no measurable activity. A buildup of HOG was confirmed in the urine, sera and liver samples from PH3 patients. To determine how HOG is cleaved in the absence of HOGA activity, the ability of N-acetylneuraminate aldolase (NAL) to cleave HOG was evaluated. NAL showed minimal activity towards HOG. Whether the expected buildup of HOG in mitochondria could inhibit glyoxylate reductase (GR), the enzyme mutated in PH2, was also evaluated. GR was inhibited by HOG but not by 2-hydroxyglutarate or 2-oxoglutarate. Thus, one hypothetical component of the molecular basis for the excessive oxalate production in PH3 appears to be the inhibition of GR by HOG, resulting in a phenotype similar to PH2.

AB - Mutations in the gene encoding for 4-hydroxy-2-oxoglutarate aldolase (HOGA) are associated with an excessive production of oxalate in Primary Hyperoxaluria type 3 (PH3). This enzyme is the final step of the hydroxyproline degradation pathway within the mitochondria and catalyzes the cleavage of 4-hydroxy-2-oxoglutarate (HOG) to pyruvate and glyoxylate. No analyses have been performed to assess the consequences of the mutations identified, particularly for those variants that produce either full-length or nearly full-length proteins. In this study, the expression, stability, and activity of nine PH3 human HOGA variants were examined. Using recombinant protein produced in Escherichia coli as well as transfected Chinese hamster ovary (CHO) cells, it was found that all nine PH3 variants are quite unstable, have a tendency to aggregate, and retain no measurable activity. A buildup of HOG was confirmed in the urine, sera and liver samples from PH3 patients. To determine how HOG is cleaved in the absence of HOGA activity, the ability of N-acetylneuraminate aldolase (NAL) to cleave HOG was evaluated. NAL showed minimal activity towards HOG. Whether the expected buildup of HOG in mitochondria could inhibit glyoxylate reductase (GR), the enzyme mutated in PH2, was also evaluated. GR was inhibited by HOG but not by 2-hydroxyglutarate or 2-oxoglutarate. Thus, one hypothetical component of the molecular basis for the excessive oxalate production in PH3 appears to be the inhibition of GR by HOG, resulting in a phenotype similar to PH2.

KW - Calcium oxalate stone disease

KW - Hydroxyproline

KW - Oxalate

UR - http://www.scopus.com/inward/record.url?scp=84864234719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864234719&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2012.06.014

DO - 10.1016/j.bbadis.2012.06.014

M3 - Article

C2 - 22771891

AN - SCOPUS:84864234719

VL - 1822

SP - 1544

EP - 1552

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 10

ER -